Takeda announces preliminary ERT trial results

Early results not as positive as hoped for

Takeda Pharmaceuticals announced that a preliminary look at the results of their recently completed phase-IIb trial of their TAK-611 ERT (enzyme replacement therapy) for MLD “topline results … did not meet primary and secondary endpoints.” The company is analyzing the results and continues to list TAK-611 in its pipeline according to statements made during this week’s earnings call.

MLD families in the trial will continue to receive infusions as part of the extension period of the trial while the rest of the data is analyzed and formal decisions are made and announced, perhaps later this year.

Remember that five different study groups are part of this trial, entering with varying levels of disease progression and ages.  

The formal analysis of this data will take some time.  The company did not formally announce what slice(s) of data were used to draw these initial conclusions.

MLD Foundation has been working with ERT researchers since 2005.  ERT is successfully used to treat other lysosomal disorders.   

Takeda Pharmaceuticals logo - 2023

Quick Fact: MLD Foundation's first meetings with Shire Human Genetic Therapies (now a part of Takeda) were in 2007 – and our first engagements with ERT researchers was in 2005 ... 18 years ago!

We are not alone on this journey …

It’s your support that has enabled and empowered us
to serve MLD families for over 22 years

Donate using the above button and also consider starting a Facebook Fundraiser!

MLD Foundation (EIN: 93-1320953) is a federally registered 501(c)(3) charity.
All donations are US tax deductible.

© 2023, All rights reserved. MLD Family is a trademark and the stylized MLD Foundation butterfly logo and We C.A.R.E. are registered trademarks of MLD Foundation.